On September 11, Moderna, Inc. rose 4.32% in regular trading, trading at $141.815/share, with turnover of $209 million, snapping a three-session losing streak.

On the news front, Berenberg significantly raised its price target on Moderna, Inc. from $45 to $100, representing a more-than-doubling adjustment, while maintaining a Hold rating. According to FactSet, the current analyst consensus rating on Moderna, Inc. is Hold, with a mean price target of $112.72. The sharp upward revision comes after the stock had retreated over the prior three trading days, during which Rothschild & Co Redburn downgraded the stock to Sell with an $81 target, while UBS maintained a Neutral rating with a $150 target, citing three upcoming individualized neoantigen therapy data readouts as potential catalysts. The continued upward revision of institutional price targets following the recent pullback provided near-term support for the share price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)